By Colin Kellaher

Celgene Corp. (CELG) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Revlimid in combination with rituximab for adults with previously treated follicular lymphoma.

The Summit, N.J., biopharmaceutical company said the combination, if approved by the European Commission, would be the first combination treatment regimen for patients with the blood cancer that doesn't include chemotherapy.

The European Commission, which generally follows the CHMP's recommendations, is expected to make its final decision in about two months, Celgene said.

Celgene in January agreed to be acquired by Bristol-Myers Squibb Co. (BMY) in a $74 billion deal expected to close by the end of the year.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 15, 2019 08:07 ET (13:07 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Celgene Charts.